You are here

Nat Rev Drug Discov DOI:10.1038/nrd.2016.155

Accelerating global innovation to address antibacterial resistance: introducing CARB-X.

Publication TypeJournal Article
Year of Publication2016
AuthorsOutterson, K, Rex, JH, Jinks, T, Jackson, P, Hallinan, J, Karp, S, Hung, DT, Franceschi, F, Merkeley, T, Houchens, C, Dixon, DM, Kurilla, MG, Aurigemma, R, Larsen, J
JournalNat Rev Drug Discov
Volume15
Issue9
Pages589-90
Date Published2016 Sep
ISSN1474-1784
Abstract

A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.

DOI10.1038/nrd.2016.155
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/27469032?dopt=Abstract

Alternate JournalNat Rev Drug Discov
PubMed ID27469032